Objectives To investigate the relationship between antidrug antibodies (ADA), adalimumab
concentrations and clinical response in patients with psoriatic arthritis (PsA) during 52 weeks …

Background Immunogenicity influences adalimumab levels and therefore clinical response
in patients with rheumatic diseases. Objectives To study the relationship between clinical …

Background: Hospital readmission rates are increasingly used as a measure of healthcare
quality. Medicines are the most common therapeutic intervention but estimating the …

Aim: For assessment of concentrations of biopharmaceuticals, for example, therapeutic drug
monitoring, dried blood sampling of capillary blood is a convenient alternative to traditional …

Objectives To identify the preventability, determinants and causes of unplanned hospital
readmissions within 30 days of discharge using a multidisciplinary approach and including …

Tumour necrosis factor inhibitors (TNFi) are effective in the majority of patients with rheumatoid
arthritis (RA), 1 however, an important reason for non-response is low drug level due to …

Aims Development of a self‐sampling method for therapeutic drug monitoring (TDM) of
biologicals will enhance TDM implementation in routine care and pharmacokinetic knowledge. …

Objective. To compare clinical outcomes, incidence of flares, and administered drug reduction
between patients with spondyloarthritis (SpA) under TNF inhibitor (TNFi) tapering strategy …

Background Increasing numbers of patients (up to 40 %) with rheumatoid arthritis (RA)
achieve remission, yet it remains to be elucidated whether this also normalizes their …

Objective. To investigate the effects of etanercept (ETN) on lipid metabolism and other known
cardiovascular disease (CVD) risk factors in patients with psoriatic arthritis (PsA). Methods. …